Charles River on hold by Jefferies

Jefferies & Co., Inc. analyst David Windley put Charles River Laboratories at a hold rating following the first day of the Life Sciences conference. The company expects to close the sale of phase 2 - 4 asset to Kendle in the third quarter. Shares of the Wilmington, Mass.-based pharmaceutical company were down 86 cents, or 2.29%, at $36.71 on volume of 609,200 shares versus the three-month running average of 792,650 shares. (NYSE: CRL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.